Cellular Biomedicine Group (CBMG)

Oncology Corporate Profile

Stock Performance

17.9400
-0.1200

3 Month Stock History Chart

HQ Location

530 University Avenue, Ste 17
Palo Alto, CA 94301

Company Description

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG?s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.

Website: http://www.cellbiomedgroup.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
C-CAR011anti-CD19 inhibitorAcute Myelogenous Leukemia (AML)I
C-CAR011anti-CD19 inhibitorDiffuse large B-cell Lymphoma (DLBCL)I

View additional information on product candidates here »

Source: http://www.cellbiomedgroup.com

Recent News Headlines

8/21/2017 06:18 am

8/21/2017 06:18 am

8/21/2017 06:18 am

8/18/2017 06:17 am

8/18/2017 06:17 am

8/13/2017 12:17 am

8/8/2017 12:17 pm

8/8/2017 12:17 pm

8/6/2017 12:20 pm

7/30/2017 12:17 pm

7/30/2017 12:17 pm

7/11/2017 12:17 pm

6/28/2017 06:17 am

6/26/2017 06:17 am

6/20/2017 12:18 am

6/20/2017 12:18 am

6/19/2017 06:18 am

6/5/2017 12:17 pm

6/2/2017 06:17 am

5/28/2017 06:17 am

4/11/2017 06:17 am

4/10/2017 12:17 pm

Cellular Biomedicine Group (CBMG) Announces Completion of Wuxi GMP Facility Expansion

3/30/2017 12:04 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., March 30, 2017-- Cellular Biomedicine Group Inc., a leading clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer ...